DIMERIX LIMITED

3.54%

54.5¢

Market Cap $327.0M

Healthcare Biotechnology

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The... Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Latest Threads

Tag

Subject

DXB

DXB Chart

40 41 42

17:45

2.4K

1.0M

17:45

Last post RYNZN

2.4K

1.0M

DXB

Ann: Quarterly Appendix 4C and Activities Report

27/07/25

8.3K

27/07/25

Last post UncleFesta

8.3K

DXB Medicine

DXB Media thread.

9 10 11

23/07/25

638

306K

23/07/25

Last post TheBrownHornet

638

306K

DXB

PARASOL

17/07/25

473

17/07/25

Last post vintage

473

DXB

Banter and general comments

2 3

16/07/25

171

73K

16/07/25

Last post BT6487

171

73K

DXB

dxb postings july 10th

10/07/25

2.3K

10/07/25

Last post kosenar

2.3K

DXB

Ann: Change of Director's Interest Notice - SP

08/07/25

3.5K

08/07/25

Last post geffa9

3.5K

DXB

Ann: Dimerix receives 1st Development Milestone payment from FUSO

02/07/25

14K

02/07/25

Last post CosmicShrug

14K

See All Discussions

Timeline

Quarterly Appendix 4C and Activities Report
25 Jul 08:35	Share

Change of Director's Interest Notice - SP
07 Jul 15:46	Share

Application for quotation of securities - DXB
01 Jul 12:23	Share

Dimerix receives 1st Development Milestone payment from FUSO
30 Jun 08:33	Share

Application for quotation of securities - DXB
27 Jun 15:22	Share

Application for quotation of securities - DXB
24 Jun 14:19	Share

Change of Director's Interest Notice - SP
23 Jun 13:27	Share

Application for quotation of securities - DXB
19 Jun 14:47	Share

Investor Presentation
19 Jun 08:21	Share

Application for quotation of securities - DXB
17 Jun 15:22	Share

ACTION3 Clinical Trial Milestone Recruitment Update
13 Jun 08:58	Share

Application for quotation of securities - DXB
12 Jun 12:02	Share

Application for quotation of securities - DXB
10 Jun 11:46	Share

Application for quotation of securities - DXB
05 Jun 15:47	Share

Application for quotation of securities - DXB
03 Jun 11:38	Share

1st ACTION3 site in Japan activated and milestone triggered
30 May 08:26	Share

Application for quotation of securities - DXB
29 May 13:28	Share

Notification of upcoming expiry of Listed Options
29 May 09:25	Share

Application for quotation of securities - DXB
27 May 14:02	Share

Application for quotation of securities - DXB
22 May 11:53	Share

Successful planned IDMC review of ACTION3 trial
22 May 08:31	Share

Change in substantial holding
20 May 13:07	Share

Application for quotation of securities - DXB
20 May 13:06	Share

Dimerix to present at Melbourne Twilight Investor Briefing
20 May 09:33	Share

Application for quotation of securities - DXB
16 May 11:31	Share

Application for quotation of securities - DXB
14 May 12:58	Share

Application for quotation of securities - DXB
12 May 13:09	Share

Application for quotation of securities - DXB
08 May 15:19	Share

Dimerix receives initial upfront payment from Amicus
06 May 08:27	Share

Application for quotation of securities - DXB
01 May 14:20	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 54.5¢		Change -0.020(3.54%)		Mkt cap ! $327.0M

Open	High	Low	Value	Volume
56.5¢	57.5¢	53.8¢	$1.076M	1.936M

Buyers (Bids)

No.	Vol.	Price($)
2	23518	54.0¢

Sellers (Offers)

Price($)	Vol.	No.
55.0¢	21500	1

View Market Depth

No.	Vol.	Price($)
2	23518	0.540
7	127844	0.535
14	178105	0.530
7	253690	0.525
14	481567	0.520

Price($)	Vol.	No.
0.550	21500	1
0.560	30000	1
0.570	2000	1
0.575	6000	1
0.580	72635	7

Last trade - 16.10pm 28/07/2025 (20 minute delay)


Last 54.0¢		Change -0.020 ( 4.42 %)
Open	High	Low	Volume
56.5¢	58.0¢	54.0¢	663866
Last updated 15.58pm 28/07/2025 ?

DXB (ASX) Chart

DIMERIX LIMITED

Latest Threads

The final ingredient SS1 needs in our "recipe for an 8,000% VUL style price run"... but ingredient #6 is the hardest one to get...

Timeline

Featured News

Latest Videos

Dimerix (ASX:DXB) to pocket $2.8m in R&D tax incentive prepayment

17 Feb 2023 10:56 (AEDT)

Dimerix (ASX:DXB) receives FDA approval to include teenagers in kidney disease study

12 Jan 2023 09:16 (AEDT)

Latest Articles

Dimerix launches key trial in Japan as recruitment kicks off

Dimerix (ASX:DXB) has kicked off a key trial in Japan (in terms of patient recruitment) seeking to treat inflammatory diseases.

Dimerix posts modest gain as first Japanese payment for DMX-200 lands

Dimerix has received the first multi-million dollar payment from its Japanese partner FUSO and expects those to continue.

Dimerix signs up first patient for 'highly significant' paediatric clinical trial

Dimerix Limited (ASX:DXB), a Melbourne-based biopharmaceutical company, has started recruitment for its first paediatric patient for the Phase 3 ACTION3 clinical trial in a major next step for the research.The trial will investigate the efficacy of DMX-200 in children aged 12 to 17 with focal seg...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News